Oral Melphalan as a Treatment for Platinum-Resistant Ovarian Cancer

British Journal of Cancer- United Kingdom

doi 10.1038/sj.bjc.6601044

Full Text

Abstract

Available in

Date

Authors

Publisher

Springer Science and Business Media LLC

Related search

Targeted Treatment of Recurrent Platinum-Resistant Ovarian Cancer: Current and Emerging Therapies

Cancer Management and Research
Oncology
2010English

Prm212 - Patient Experience With Platinum-Resistant or Platinum-Refractory Ovarian Cancer

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Is HIPEC Beneficial in Platinum Resistant Relapsed Ovarian Cancer?

Romanian Journal of Medical Practice
2019English

The Use of Treosulfan and Gemcitabine in the Treatment of Platinum-Resistant Ovarian Cancer

Oncology Letters
Cancer ResearchOncology
2010English

Emerging Role for Bevacizumab in Combination With Chemotherapy for Patients With Platinum-Resistant Ovarian Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2014English

Exosomes as Mediators of Platinum Resistance in Ovarian Cancer

Oncotarget
Oncology
2017English

Pcn333 - Real-World Treatment Patterns of Patients With Advanced (Stage Ii-Iv) Ovarian Cancer Classified as Resistant or Refractory to Frontline Platinum-Based Therapy

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

[18F]Fluciclatide PET as a Biomarker of Response to Combination Therapy of Pazopanib and Paclitaxel in Platinum-Resistant/Refractory Ovarian Cancer

European Journal of Nuclear Medicine and Molecular Imaging
MedicineNuclear MedicineRadiologyImaging
2019English

Chemotherapy-Free Strategy for Platinum-Sensitive Recurrent Ovarian Cancer

The Lancet Oncology
Oncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy